Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Common Equity (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Common Equity for 4 consecutive years, with $8.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 185.23% to $8.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a 185.23% increase, with the full-year FY2024 number at $2.6 million, down 46.41% from a year prior.
  • Common Equity was $8.9 million for Q3 2025 at bioAffinity Technologies, up from -$2.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $12.6 million in Q3 2022 to a low of -$16.8 million in Q2 2022.
  • A 4-year average of $2.8 million and a median of $4.9 million in 2023 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 185.23% in 2025; the steepest drop was 162.22% in 2025.
  • bioAffinity Technologies' Common Equity stood at $11.0 million in 2022, then crashed by 56.03% to $4.9 million in 2023, then crashed by 46.41% to $2.6 million in 2024, then surged by 242.12% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Common Equity are $8.9 million (Q3 2025), -$2.1 million (Q2 2025), and $1.4 million (Q1 2025).